AIDS
Disease characteristics
AIDS (Acquired Immune Deficiency Syndrome) is a disease that is induced in the final stage that appears as a lack of immunity, helping the body to protect against infections.
Disease organ or body part
Initially the number of lymphocytes falls below the critical threshold and opportunistic infections begin.
Nervous, respiratory, digestive, urogenital, skin, and finally death from infection.
Children account for 1% of AIDS patients and die.
About 10 years later, people living with HIV live 2-3 years before the emergence of AIDS.
Africa is an HIV and AIDS-related socio-economic crisis because most patients are functioning and reach age.
Cause of illness
Terminate all risks of HIV infection, trigger lymphocyte count when AIDS occurs, and HIV infection.
Vaccines against the most common infectious diseases, preventive use of antibiotics, infectious diseases, and avoiding other infectious diseases, although there is no reduction in lymphocytes as a target of preventive measures.
Symptoms and signs
Common signs are weakness, weight loss, night sweats
Dysphagia, painful oral mucosa
Respiratory distress, cough, chest pain
Nausea, vomiting, diarrhea, abdominal pain
Lesions and rashes
Nervous system: Injured mind, mental retardation, paralysis
Mental symptoms: depression, suicide
Weakness, bleeding, pale skin
Diagnosis of disease
The test reveals opportunistic infections.
Head, eyes, ears, throat-oral candidiasis, leukoplakia, retinitis, otitis media, tonsillitis.
Lymph node swelling (lymph node enlargement), stiff neck
Signs of meningitis
Respiratory system-increased lung tissue integration.
Liver and spleen
Neurological symptoms-meningitis, dementia, neurological local symptoms (neurological defect status)
Spotted, hill rash (red spots on the skin also appear in blisters), folliculitis, certain herpes simplex, Kaposi sarcoma, drug rash
Hematopoietic system-anemia, blood coagulation disorder, (gum, mouth, intestinal mucosa, bleeding punctate, ecchymosis)
) HIV-1 p24 (HIV-1) | |||
| GWB-420F7B | 0.1 mg | Ask for price | |
 recomLine HIV-1 & HIV-2 IgG | |||
| MBS191644-20Tests | 20Tests | 1005 EUR | |
recomLine HIV-1 & HIV-2 IgG | |||
| MBS191644-5x20Tests | 5x20Tests | 4505 EUR | |
 recombinant) HIV-1 p24 (HIV-1) recombinant | |||
| GWB-FE5FE0 | 0.1 mg | Ask for price | |
 HIV-1, HIV-2 Protease Substrate | |||
| MBS8246618-10mg | 10mg | 560 EUR | |
HIV-1, HIV-2 Protease Substrate | |||
| MBS8246618-1mg | 1mg | 225 EUR | |
HIV-1, HIV-2 Protease Substrate | |||
| MBS8246618-5mg | 5mg | 400 EUR | |
HIV-1, HIV-2 Protease Substrate | |||
| MBS8246618-5x10mg | 5x10mg | 2435 EUR | |
HIV-1, HIV-2 Protease Substrate | |||
| 5-01313 | 4 x 5mg | 229.32 EUR | |
 Purified Azide Free) Anti-HIV protease (HIV-1/HIV-2) Purified Azide Free | |||
| 10-302-C025 | 0.025 mg | 77 EUR | |
Anti-HIV protease (HIV-1/HIV-2) Purified Azide Free | |||
| 10-302-C100 | 0.1 mg | 154 EUR | |
Anti-HIV protease (HIV-1/HIV-2) Purified Azide Free | |||
| MBS1800056-01mg | 0.1mg | 270 EUR | |
Anti-HIV protease (HIV-1/HIV-2) Purified Azide Free | |||
| MBS1800056-5x01mg | 5×0.1mg | 960 EUR | |
) HIV-1 IIIB p17 (HIV-1 IIIB) | |||
| GWB-ECCEE5 | 0.1 mg | Ask for price | |
 HIV-1 | |||
| 1901 | 1 ml | 225 EUR | |
HIV-1 | |||
| 1911 | 100 ug | 300 EUR | |
HIV-1 | |||
| 1941 | 100 ug | 280 EUR | |
HIV-1 | |||
| 1946 | 100 ug | 300 EUR | |
HIV-1 | |||
| 1947 | 100 ug | 300 EUR | |
HIV-1 | |||
| 1948 | 100 ug | 300 EUR | |
HIV-1 | |||
| 1949 | 100 ug | 300 EUR | |
HIV-1 | |||
| 1951 | 1 ml | 235 EUR | |
HIV-1 | |||
| 1961 | 1 ml | 235 EUR | |
HIV-1 | |||
| 1971 | 1 ml | 235 EUR | |
HIV-1 | |||
| 1981 | 100 ug | 280 EUR | |
HIV-1 | |||
| 1996 | 100 ug | 300 EUR | |
HIV-1 | |||
| 8908 | 100 ug | 490 EUR | |
HIV-1 | |||
| 8909 | 100 ug | 440 EUR | |
 HIV-2 | |||
| 8911 | 100 ug | 490 EUR | |
HIV-1 | |||
| 8933 | 100 ug | 340 EUR | |
HIV-1 | |||
| 8941 | 100 ug | 340 EUR | |
HIV-2 | |||
| 8949 | 100 ug | 380 EUR | |
HIV-1 | |||
| 9000 | 100 ug | 345 EUR | |
HIV-1 | |||
| 9001 | 100 ug | 345 EUR | |
HIV-1 | |||
| 9002 | 100 ug | 520 EUR | |
HIV-2 | |||
| 9003 | 100 ug | 345 EUR | |
 HIV-1,2 | |||
| hiv-131 | 100µg | 165 EUR | |
HIV-1 | |||
| MBS320413-01mg | 0.1mg | 390 EUR | |
HIV-1 | |||
| MBS320413-5x01mg | 5×0.1mg | 1660 EUR | |
) HIV-1 nef Recombinant (HIV-1 nef) | |||
| PT_40983 |
|
|
|
) HIV-1 p24 Recombinant (HIV-1 p24) | |||
| PT_40989 |
|
|
|
) HIV-1 gp41 Recombinant (HIV-1 gp41) | |||
| PT_40970 |
|
|
|
) HIV-2 gp32 Recombinant (HIV-2 gp32) | |||
| PT_41007 |
|
|
|
) HIV-2 gp36 Recombinant (HIV-2 gp36) | |||
| PT_41011 |
|
|
|
) HIV-1 envelope conjugated to HIV-2 gp39 Recombinant (HIV-1, 2) | |||
| PT_41016 |
|
|
|
 HIV-1, HIV-2 Protease Substrate Peptide | |||
| abx265644-100tests | 100 tests | 400 EUR | |
HIV-1, HIV-2 Protease Substrate Peptide | |||
| 20-abx265644 |
|
|
|
HIV-1, HIV-2 Protease Substrate Peptide | |||
| abx265644-200tests | 200 tests | 700 EUR | |
HIV-1, HIV-2 Protease Substrate Peptide | |||
| abx265644-50tests | 50 tests | 287.5 EUR | |
 HIV-1 HIV-2 Protease Substrate Peptide | |||
| PE-101043 |
|
|
|
) HIV-1 Envelope Recombinant (HIV-1 Envelope) | |||
| PT_40961 |
|
|
|
) HIV-2 Envelope Recombinant (HIV-2 Envelope) | |||
| PT_41006 |
|
|
|
) HIV-2 Protease Recombinant (HIV-2 Protease) | |||
| PT_73647 |
|
|
|
) HIV-1 Protease Recombinant (HIV-1 Protease) | |||
| PT_73664 |
|
|
|
) HIV-1 Integrase Recombinant (HIV-1 Integrase) | |||
| PT_40981 |
|
|
|
 Recombinant) HIV Reverse Transcriptase (HIV-RT) Recombinant | |||
| GWB-56D50E | 0.025 mg | Ask for price | |
 HIV Rev | |||
| GWB-96E989 | 0.05 ml | Ask for price | |
 HIV QK10 | |||
| MBS8246609-10mg | 10mg | 560 EUR | |
HIV QK10 | |||
| MBS8246609-1mg | 1mg | 225 EUR | |
HIV QK10 | |||
| MBS8246609-5mg | 5mg | 400 EUR | |
HIV QK10 | |||
| MBS8246609-5x10mg | 5x10mg | 2435 EUR | |
 HIV gp27 | |||
| 117538 | 100 µg | Ask for price | |
 HIV gp24 | |||
| 117539 | 100 µg | Ask for price | |
HIV QK10 | |||
| 5-01336 | 4 x 5mg | 204.75 EUR | |
 HIV-TAT | |||
| GWB-A604C3 | 0.05 ml | Ask for price | |
] GP120) Recombinant HIV-01 [HIV-01/Clade C (16055)] GP120 | |||
| VAG334 |
|
|
|
] GP120) Recombinant HIV-01 [HIV-01/Clade E (CM244)] GP120 | |||
| VAG335 |
|
|
|
) RT (HIV-1) | |||
| GWB-614E0A | 0.1 mg | Ask for price | |
 HIV-1 Ag | |||
| GWB-9E89D6 | 1 mg | Ask for price | |
RT (HIV-1) | |||
| GWB-E6CA8B | 0.5 ml | Ask for price | |
RT (HIV-1) | |||
| GWB-FC0114 | 0.1 mg | Ask for price | |
 HIV-1 p24 | |||
| MBS8506672-1mg | 1mg | 780 EUR | |
HIV-1 p24 | |||
| MBS8506672-5x1mg | 5x1mg | 3365 EUR | |
HIV-1 p24 | |||
| MBS8506844-01mg | 0.1mg | 325 EUR | |
HIV-1 p24 | |||
| MBS8506844-5x01mg | 5×0.1mg | 1320 EUR | |
 HIV-1 Nef | |||
| 05-011 | 50 ug | 434.4 EUR | |
HIV-1 Nef | |||
| 05-012 | 250 ug | 1154.4 EUR | |
HIV-1 p24 | |||
| ant-152 | 0.5mg | 275 EUR | |
HIV-1 p24 | |||
| E5-00024 | 1mg | 700 EUR | |
HIV-1 p24 | |||
| E62H002 | 100ug | 255 EUR | |
HIV-1 p24 | |||
| GWB-1A0810 | 1 mg | Ask for price | |
HIV-1 p24 | |||
| GWB-3A5505 | 0.1 mg | Ask for price | |
) p24 (HIV-1) | |||
| GWB-549FE4 | 0.5 ml | Ask for price | |
 HIV-1 REV | |||
| GWB-68E36D | 0.1 mg | Ask for price | |
HIV-1 p24 | |||
| GWB-B96BB9 | 1 mg | Ask for price | |
HIV-1 REV | |||
| GWB-C080E6 | 0.1 mg | Ask for price | |
) TAT (HIV-1) | |||
| GWB-D5D417 | 0.1 mg | Ask for price | |
HIV-1 p24 | |||
| hiv-006 | 100µg | 130 EUR | |
 HIV-1 CRF | |||
| hiv-008 | 2µg | 60 EUR | |
 HIV-1 GAG | |||
| hiv-010 | 2µg | 60 EUR | |
 HIV-2 gag | |||
| hiv-015 | 100µg | 200 EUR | |
 HIV-1 p30 | |||
| hiv-016 | 100µg | 200 EUR | |
 HIV-1 nef | |||
| hiv-124 | 100µg | 165 EUR | |
Clinical examination
The blood prescribes specific antibodies against HIV.
Arterial blood gas-hypoxia levels are usually caused by carini (indicating pneumonia).
Blood cell loss, anemia, electrolyte imbalance, urea level
Cultivated from blood cultures containing fungi and tuberculosis, positive blood bacterial cultures.
Regular fecal crop
Target, liver, pancreas, kidney damage
Disease treatment
Treatment covers opportunistic infections and supportive care (oxygen therapy, fluid loss and recovery, etc.).
They were also treated intensively with antiretroviral therapy (see HIV infection).
Many bacteria with antibiotics (such as imipenem, metronidazole, vancomycin and azithromycin), antifungal drugs (such as amphotericin B, clotrimazole), antiviruses (acyclovir, ganciclovir, valacyclovir, foscarnet), parasites, pharmaceuticals ( Pentamidine).
Glucocorticoids, vincristine, blood transfusions, spleen removal used to treat thrombocytopenia.
Used to treat fetal blood stimulants (erythropoietin).
Prognosis is poor, with appropriate treatment, survival is not more than 3 years.
It is therefore very important to apply prevention of HIV exposure (see HIV infection).